Navigation Links
Elusys Releases New Data On Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies
Date:7/31/2013

bed to anthrax while the group treated with 16 mg/kg at that time point showed 50% (3/6) survival. All animals treated with placebo at 18 hours post-challenge succumbed to anthrax.

The second study was a randomized, four-arm, placebo-controlled, post-challenge, timed-treatment study. Animals were treated with a single dose of ETI-204 (16 mg/kg IM) at 24, 36 or 48 hours after challenge with aerosolized B. anthracis spores. The primary endpoint was survival at 28 days after spore challenge. The group treated with ETI-204 (16 mg/kg IM) 24 hours post-challenge demonstrated a survival rate of 93% (13/14) which was statistically significantly higher than the 10% (1/10) survival rate seen in the control group. The groups treated with ETI-204 at 36 or 48 hours post-challenge demonstrated survival rates of 43% (6/14) and 29% (4/14), respectively. 

A planned secondary analysis revealed that 100% (15/15) of animals dosed with ETI-204 before becoming bacteremic (having evidence of bacteria in the blood stream) survived, and 30% (8/27) of animals dosed with ETI-204 after becoming bacteremic survived. These results were presented, in part, at the recent ASM Biodefense and Emerging Diseases Research Meeting, Washington, DC, February 2013.

A third study examined the pre-challenge protection duration of ETI-204. The study was a randomized, blinded, four-arm, placebo-controlled study in animals dosed with ETI-204 prior to challenge with B. anthracis spores. Animals were administered a single dose of ETI-204 (16 mg/kg IM) at either 24, 48 or 72 hours prior to challenge with aerosolized B. anthracis spores. The primary endpoint was survival at 56 days after challenge. All animals receiving ETI-204 survived to 56 days post-challenge, regardless of the time ETI-204 was administered prior to challenge. Ninety percent (9/10) of animals dosed with placebo prior to challenge died within the first 14 days following
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Elusys Awarded Additional $50.2 Million Under An Exisiting U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax
2. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
3. HCCS Releases ICD-10 Countdown Clock With Integrated CMS Twitter Tweets
4. eCareSoft Releases eCS Cirrus™
5. AtheroNova Releases 2011 Financial Results
6. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
7. ILVO-T&V Belgium Releases Validation Report of the Charm Sciences Beta-lactam and Tetracycline 2-minute Test for Raw Commingled Milk
8. ISPE Releases New Guidance for Designing and Constructing Packaging, Labeling and Warehousing Facilities
9. Happtique Releases Draft App Certification Program Standards For Public Comment
10. ClearCanvas Releases New Workstation Products Designed to Assist With Image Sharing
11. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MO (PRWEB) July 28, 2014 ... and services that bring the power of genomics to ... inaugural Appistry Pipeline Challenge . , Two ... president of the National Center for Genome Resources, and ... Hospitals and Clinics of Kansas City. Rounding out the ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
(Date:7/28/2014)... The National Model Aviation Museum, located ... pleased to announce that it has been granted full ... United States Air Force. , The certification is the ... this spring with an on-site inspection by Sarah Sessions, ... The National Museum of the United States Air ...
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
(Date:7/25/2014)... A study published online in the International ... novel approach to preventing cervical cancer based on findings ... after removal of a discrete population of cells in ... study that looked at squamocolumnar junction cells, or SCJ ... have been implicated as the origins of cervical cancer. ...
(Date:7/25/2014)... characterized by the existence of numerous isoforms arising ... the protein deeply different characteristics. NRG1 plays an ... development and the different phases occurring after injury ... remyelination and target reinnervation, Researchers at the University ... NRG1 upregulation observed in Schwann cells immediately after ...
(Date:7/25/2014)... of a molecular testing panel developed at UPMC ... initial surgery for patients with thyroid nodules and ... Cancer Institute (UPCI), partner with UPMC CancerCenter., The ... and other diagnostic testing agencies, improved the chances ... 30 percent, according to the study published this ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... of genetic regions known to be implicated in Crohn,s disease, ... research, published today in the journal Nature Genetics , ... development as well as providing surprising new links between the ... disease affects between 1 in 500 and 1 in 1000 ...
... choosing mates. Flowering plant pollination systems are clever ... there are also mechanisms for keeping out unwanted pollen. ... reject such pollen because of the deleterious effects of inbreeding. ... close relatives is rejected if it lands on the female ...
... Two Montana state University researchers are principal editors on ... ways to study carnivores in the wild. "Noninvasive ... June 27 with Robert Long and Paula MacKay as ... Western Transportation Institute. Working with two co-editors ...
Cached Biology News:Complexity of Crohn's disease revealed as 'gene' count tops 30 2Complexity of Crohn's disease revealed as 'gene' count tops 30 3Mate choice in plants 2Mate choice in plants 3
... Cultrex High Protein Concentration Basement Membrane ... use in in vivo applications where ... times, increased gel strength, and elevated ... has the advantage of lot-to-lot consistency ...
mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
...
...
Biology Products: